127 related articles for article (PubMed ID: 30555023)
21. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of miR-216b: Prognostic and predictive value in acute myeloid leukemia.
Zhang TJ; Wu DH; Zhou JD; Li XX; Zhang W; Guo H; Ma JC; Deng ZQ; Lin J; Qian J
J Cell Physiol; 2018 Apr; 233(4):3274-3281. PubMed ID: 28884855
[TBL] [Abstract][Full Text] [Related]
24. Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.
Seyyedi SS; Soleimani M; Yaghmaie M; Ajami M; Ajami M; Pourbeyranvand S; Alimoghaddam K; Akrami SM
Tumour Biol; 2016 Apr; 37(4):4841-7. PubMed ID: 26526573
[TBL] [Abstract][Full Text] [Related]
25. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
26. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
27. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
28. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
[TBL] [Abstract][Full Text] [Related]
29. Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Damm F; Oberacker T; Thol F; Surdziel E; Wagner K; Chaturvedi A; Morgan M; Bomm K; Göhring G; Lübbert M; Kanz L; Fiedler W; Schlegelberger B; Heil G; Schlenk RF; Döhner K; Döhner H; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Feb; 29(6):682-9. PubMed ID: 21205756
[TBL] [Abstract][Full Text] [Related]
30. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
[TBL] [Abstract][Full Text] [Related]
31. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.
Thol F; Winschel C; Sonntag AK; Damm F; Wagner K; Chaturvedi A; Göhring G; Schlegelberger B; Lübbert M; Fiedler W; Kirchner H; Krauter J; Ganser A; Heuser M
Ann Hematol; 2013 Mar; 92(3):315-23. PubMed ID: 23233047
[TBL] [Abstract][Full Text] [Related]
34. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
35. IER3 (IEX-1) dysregulation serves as a potential prognostic factor in acute myeloid leukemia patients.
Ke S; Zhang X; Xiang X; Lu Y; An H
Int J Lab Hematol; 2022 Apr; 44(2):342-348. PubMed ID: 34729939
[TBL] [Abstract][Full Text] [Related]
36. Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia.
Yang WC; Lin PM; Yang MY; Liu YC; Chang CS; Chou WC; Hsu JF; Huang CT; Cho SF; Yu WH; Lin SF
Leuk Lymphoma; 2013 Aug; 54(8):1614-25. PubMed ID: 23150981
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
38. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
39. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
[TBL] [Abstract][Full Text] [Related]
40. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
